Current Cancer Drug Targets
Volume 22, 11 Issues, 2022
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
Contents
Current Cancer Drug Targets , Volume 13 - Number 3
Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
, 13(3): 234 - 244Mitchell Cheung and Joseph R. Testa
DOI: 10.2174/1568009611313030002
Oxygen-independent Regulation of HIF-1: Novel Involvement of PI3K/ AKT/mTOR Pathway in Cancer
, 13(3): 245 - 251Faton Agani and Bing-Hua Jiang
DOI: 10.2174/1568009611313030003
Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
, 13(3): 252 - 266Richard L. Carpenter and Bing-Hua Jiang
DOI: 10.2174/1568009611313030004
Targeting the mTOR Pathway in Tumor Malignancy
, 13(3): 267 - 277Hengmiao Cheng, Marlena Walls, Sangita M. Baxi and Min-Jean Yin
DOI: 10.2174/1568009611313030005
IDO+ DCs and Signalling Pathways
, 13(3): 278 - 288Yue Wang, Bao-Hong Yang, Hui Li, Shui Cao, Xiu-Bao Ren and Jin-Pu Yu
DOI: 10.2174/15680096113139990073
Novel HSP90 Inhibitor NVP-AUY922 Enhances the Anti-tumor Effect of Temsirolimus Against Oral Squamous Cell Carcinoma
, 13(3): 289 - 299Tatsuo Okui, Tsuyoshi Shimo, Takuya Fukazawa, Nur Mohammad Monsur Hassan, Tatsuki Honami, Soichiro Ibaragi, Munenori Takaoka, Yoshio Naomoto and Akira Sasaki
DOI: 10.2174/1568009611313030007
Targeting Tyrosine Kinase Receptors in Hepatocellular Carcinoma
, 13(3): 300 - 312Jordi Muntane, Angel J. De la Rosa, Fernando Docobo, Rocio Garcia-Carbonero and Francisco J. Padillo
DOI: 10.2174/15680096113139990075
Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?
, 13(3): 313 - 325Matteo Santoni, Mimma Rizzo, Luciano Burattini, Rossana Berardi, Giacomo Carteni and Stefano Cascinu
DOI: 10.2174/1568009611313030009
P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
, 13(3): 326 - 346Ziyad Binkhathlan and Afsaneh Lavasanifar
DOI: 10.2174/15680096113139990076
Editor-in-Chief
Ruiwen Zhang
Center for Drug Discovery
University of Houston
Houston, TX
(USA)
Biography
Center for Drug Discovery
University of Houston
Houston, TX
Biography
Biography of Ruiwen Zhang
Ruiwen Zhang is the Robert L. Boblitt Endowed Professor in Drug Discovery and Director of the Drug Discovery Institute at the University of Houston. With over 30 years of experience in the field of biomedical research, particularly in the area of clinical pharmacology and therapeutics, pharmaceutical and toxicological research, Dr. Zhang’s research has been continuously funded by NIH and DoD, and other agencies. He has published more than 230 papers, 2 books, and more than 50 invited reviews/book chapters as well as more than 180 meeting abstracts. For his outstanding contributions in pharmaceutical sciences, Dr. Zhang was elected as a Fellow of American Association for the Advancement of Science (AAAS) in 2009. Dr. Zhang is recently elected as Fellow of National Academy of Inventors (2018).
COPE Compliant
About the Journal
⇨ Journal Home⇨ Editorial Policies⇨ Fabricating and Stating False Information⇨ Research Misconduct⇨ Post Publication Discussions and Corrections⇨ Allegations from Whistleblowers⇨ Editorial Board⇨ Meet the Executive Guest Editor(s)⇨ Board Recruitment Workflow⇨ Join Editorial Board⇨ Indexing Information⇨ Announcements⇨ Endorsements⇨ Authors' Comments
For Authors
For Librarians & Readers
Quick Links
Journal History
Current Cancer Drug Targets was launched in 2001. Dr. Ruiwen Zhang serves as the Editor-in-Chief of the journal.
Advertisement
Webmaster Contact: info@benthamscience.net